Form 4: Teladoc Health Officer Sells Shares for Tax Obligations

Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding.

Summary

• Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported transactions involving company securities.
• On January 2, 2026, 2,083 restricted stock units (RSUs) converted into common stock.
• On January 5, 2026, 758 shares of common stock were sold at a price of $7.145 per share.
• The sale was conducted specifically to cover tax withholding obligations arising from the vesting of the reporting person's restricted stock unit awards.
• Following these reported transactions, Catapano beneficially owns 6,686 shares of common stock directly and 14,584 derivative securities (restricted stock units).
• An initial grant of 25,000 restricted stock units was made on October 1, 2024, with a vesting schedule of one-third on the first anniversary of the grant date, and the remainder in eight substantially equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (RSU vesting and tax-related sale) which are common and do not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The vesting of restricted stock units represents a component of the Chief Accounting Officer's compensation, indicating continued alignment with company performance.

Negatives

• A sale of 758 shares of common stock occurred, reducing the officer's direct common stock holdings, although this was for tax withholding purposes.

Future Outlook

The filing does not provide forward-looking statements or guidance beyond the established vesting schedule for the remaining restricted stock units.

Management Comments

• Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock unit awards.

Industry Context

This routine insider transaction, involving the vesting of restricted stock units and a subsequent tax-related sale, is a common occurrence across various industries for executive compensation and does not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The reported transactions are standard practice for executive compensation plans involving restricted stock units across publicly traded companies.
• The sale of shares to cover tax withholding upon vesting is a common and expected event, aligning with typical industry compensation and tax management practices.
• No specific comparable companies, projects, or results are detailed in this filing for direct comparison.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine insider transaction for compensation and tax purposes, not indicative of a change in company fundamentals or strategy.
• Employees: No direct impact on the broader employee base is mentioned in this filing.

Next Steps

• Remaining restricted stock units granted on October 1, 2024, will continue to vest according to the established schedule (one-third on the first anniversary of the grant date, with the remainder in eight substantially equal quarterly installments thereafter).

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Chief Accounting Officer, Stock Sale, Tax Withholding